Experimental nephrotic syndrome results in sodium retention, reflecting, at least in part, an intrinsic defect in renal sodium handling in the distal nephron. We studied the relationships among plasma atrial natriuretic peptide (ANP) concentration, sodium excretion (UNaV), and urinary cyclic GMP excretion (UcGMPV) in vivo, and the responsiveness of isolated glomeruli and inner medullary collecting duct (IMCD) cells to ANP in vitro, in rats with adriamycin nephrosis (6-7 mg/kg body weight, intravenously). 3-5 wk after injection, rats were proteinuric and had a blunted natriuretic response to intravenous infusion of isotonic saline, 2% body weight given over 5 min. 30 min after onset of the infusion, plasma ANP concentrations were elevated in normals and were even higher in nephrotics. Despite this, nephrotic animals had a reduced rate of UcGMPV after the saline infusion, and accumulation of cGMP by isolated glomeruli and IMCD cells from nephrotic rats after incubation with ANP was significantly reduced compared to normals. This difference was not related to differences in binding of 125I-ANP to IMCD cells, but was abolished when cGMP accumulation was measured in the presence of 10(-3) M isobutylmethylxanthine or zaprinast (M&B 22,948), two different inhibitors of cyclic nucleotide phosphodiesterases (PDEs). Infusion of zaprinast (10 micrograms/min) into one renal artery of nephrotic rats normalized both the natriuretic response to volume expansion and the increase in […] 
Introduction
Experimental nephrotic syndrome results in sodium retention, reflecting, at least in part, an intrinsic defect in renal sodium handling in the distal nephron. We studied the relationships among plasma atrial natriuretic peptide (ANP) concentration, sodium excretion (UN.V), and urinary cyclic GMP excretion (UCGMPV) in vivo, and the responsiveness of isolated glomeruli and inner medullary collecting duct (IMCD) cells to ANP in vitro, in rats with adriamycin nephrosis (6-7 mg/kg body weight, intravenously). 3-5 wk after injection, rats were proteinuric and had a blunted natriuretic response to intravenous infusion of isotonic saline, 2% body weight given over 5 min. 30 min after onset of the infusion, plasma ANP concentrations were elevated in normals and were even higher in nephrotics.
Despite this, nephrotic animals had a reduced rate of UGmpV after the saline infusion, and accumulation ofcGMP by isolated glomeruli and IMCD cells from nephrotic rats after incubation with ANP was significantly reduced compared to normals. This difference was not related to differences in binding of 125I-ANP to IMCD cells, but was abolished when cGMP accumulation was measured in the presence of 0-3 M isobutylmethylxanthine or zaprinast (M&B 22,948) , two different inhibitors of cyclic nucleotide phosphodiesterases (PDEs). Infusion of zaprinast (10 Atg/min) into one renal artery of nephrotic rats normalized both the natriuretic response to volume expansion and the increase in UCGmpV from the infused, but not the contralateral, kidney.
These results show that, in adriamycin nephrosis, blunted volume expansion natriuresis is associated with renal resistance to ANP, demonstrated both in vivo and in target tissues in vitro. The resistance does not appear related to a defect in binding of the peptide, but is blocked by PDE inhibitors, suggesting that enhanced cGMP-PDE activity may account for resistance to the natriuretic actions of ANP observed in vivo. This defect may represent the intrinsic sodium transport abnormality linked to sodium retention in nephrotic syndrome. (J. Clin. Invest. 1992 . 90:1302-1312.) Key words: atrial natriuretic peptide * cyclic guanosine monophosphate * glomeruli* inner medullary collecting duct * phosphodiesterase * resistance Abnormal sodium metabolism leading to the pathological retention ofsodium is a hallmark ofboth clinical and experimental nephrotic syndrome. Two major theories have been offered to account for the development of nephrotic edema (1) . In one, functionally intact kidneys (with respect to sodium handling) retain sodium in response to signals arising from an underfilled circulation, the latter resulting from the transfer of plasma water to the interstitium secondary to hypoalbuminemia. According to this theory, the sodium retention occurs in a manner identical to that resulting from any other hypovolemic stimulus, and is characterized in part by increases in filtration fraction and renal vascular resistance, enhanced fractional reabsorption offiltrate in the proximal tubule, heightened sympathetic renal nerve activity, activation of the renin-angiotensin system, and a reduced concentration of atrial natriuretic peptide (ANP)' in plasma. Numerous clinical and experimental observations document these patterns ofrenal function in at least some forms of nephrotic syndrome and thereby support the so-called "underfill" mechanism of edema formation (2) (3) (4) (5) (6) (7) (8) .
An alternative theory argues that an intrinsic defect in the tubular handling of sodium by the nephrotic kidney results in increased reabsorption of filtered sodium, most likely in distal nephron segments. This increased reabsorption leads to positive sodium balance and extracellular fluid volume expansion whereby subsequent edema formation occurs on an "overflow" basis ( 1 ). Among the characteristics of renal function in this setting are a reduced filtration fraction, normal or decreased proximal reabsorption, and suppression of the reninangiotensin system. A number of observations are consistent with this formulation of the pathophysiology of nephrotic edema (2, (9) (10) (11) (12) (13) (14) (15) .
Two models of experimental nephrosis have been particularly useful in exploring nephrotic sodium metabolism, those resulting from the intravenous administration ofthe aminonucleoside of puromycin ( 16) and of adriamycin ( 17) . These agents regularly produce high-grade proteinuria in the rat without marked histologic change early, whereas glomerulosclerosis usually develops later in the course. For each agent, abnormalities in sodium handling can be shown to be intrinsic to the kidneys; unilateral administration leads to blunted natriuresis only of the involved, proteinuric kidney, a finding which supports the "overflow" model of nephrotic edema ( 12, 18) .
Recent studies carried out in rats with nephrosis resulting from adriamycin administration have suggested that the ab-normal sodium metabolism accompanying this disorder could reflect impaired responsiveness to circulating ANP (19) (20) (21) . This resistance to the natriuretic action of ANP and the blunted natriuresis seen after volume expansion in these rats were shown to improve after renal denervation (7, 19) . To explore these phenomena further, we have examined the relationship between the natriuretic response to extracellular fluid volume expansion and circulating ANP levels as well as urinary cyclic GMP excretion (an index ofANP bioactivity in the kidneys) in normal and nephrotic rats. In addition, we have explored more directly the effect of ANP on renal tissue from normal compared to nephrotic animals by using freshly dispersed glomeruli and inner medullary collecting duct (IMCD) cells to assess ANP binding activity and ANP-dependent cGMP accumulation. Our results support the hypothesis of relative ANP resistance in adriamycin nephrosis but suggest that this could reflect an intracellular defect that is not mediated solely through enhanced renal nerve activity.
Methods
All studies were carried out under protocols reviewed and approved by the Committee on Animal Research of the University of California, San Francisco. Experimental nephrotic syndrome was induced by the administration of 1 mg of adriamycin (doxorubicin HCl, Sigma) in 1 ml of normal saline by tail vein to male Sprague-Dawley rats weighing 150-180 g (6-7 mg/kg body weight). These animals were studied 3-5 wk later, at which time 24-h urinary protein excretion (collected in a metabolic cage) averaged 530±34 (SE) mg (n = 39); adriamycintreated rats in whom proteinuria was not quantitated had qualitative albuminuria of 4+ by a color reagent (Ames Labstix, Miles Inc., Elkhart, IN). Normal control rats underwent no injection but were studied at the same age. All animals were allowed free access to standard laboratory rat diet and tap water and were housed in a constant temperature environment with a 12-h light-dark cycle.
In vivo studies. We carried out renal clearance studies in anesthetized rats that weighed between 250 and 320 g at the time ofexperimentation. For acute experimentation they were anesthetized with Inactin (Andrew Lockwood & Assoc., Sturtevant, WI) 120 mg/kg intraperitoneally, and placed on a heated operating table to maintain rectal temperature at 37±0.5°C. A tracheostomy tube was placed and fine polyethylene catheters were inserted into a femoral vein for infusion of solutions and into a femoral artery for obtaining blood samples and monitoring arterial blood pressure. Pressure was recorded with a Statham model P23id pressure transducer (Gould Instruments, Inc., Oxnard, CA) attached to a polygraph recorder (model 7D, Grass Instruments, Quincy, MA). Urine was collected into preweighed plastic vials via a flanged catheter inserted into the urinary bladder by means of a small suprapubic incision.
All animals received an intravenous infusion ofnormal saline at 2.4 ml/h from the completion ofsurgery through the duration ofthe study. In most experiments this solution contained sufficient meglumine iothalamate (Conray 60, Mallinkrodt, Inc., St. Louis, MO) to permit the determination of the clearance of iothalamate (Cio) as an estimate ofglomerular filtration rate (GFR). A 60-min interval elapsed after the completion ofsurgery to allow for equilibration ofthe infusion solution and recovery from surgical preparation. Then, two timed urine collections were obtained (C1, C2) as was a 200-gl blood sample, collected in heparinized glass capillary tubes, at the midpoint of each period. We next administered a volume of normal saline equal to 2% of the rat's weight intravenously over a 5-min interval. In many cases, iothalamate was included in this saline infusion to minimize alterations in plasma iothalamate concentration, thereby permitting more accurate determination of C;-. phosphate dibasic (0.025 M) and hydrated citric acid (0.025 M), to which 34 Ml of Na2EDTA (0.005 mM), and 70 mg of octyl sodium sulfate were added. To 950 ml ofthis buffer was added 40 ml ofmethanol, 10 ml of isopropanol, and 250 Ml of triethylamine. The mixture was then adjusted to final pH 3.9 by dropwise addition of phosphoric acid. Eluted catecholamines were detected electrochemically using a detector (Bioanalytical Systems Inc., W. Lafayette, IN). Quantitation was achieved using peak height ratios. RIA ofANP concentration in plasma. Plasma samples were thawed in the cold and extracted with Sep Pak C18 cartridges (Waters Inc., Milford, MA) that had been preequilibrated with 0.1% trifluoroacetic acid (TFA) as described previously (23) . The sample was eluted with 75% methanol in 0.1% TFA and then evaporated to dryness under a nitrogen stream; samples were stored at -70'C until assayed. For the assay, the samples were reconstituted in assay buffer and ANP immunoreactivity measured in duplicate using commercially available antisera (Research and Diagnostics, Emeryville, CA), '25I-rANPI-28 labeled using the chloramine-T method, and unlabeled rANP,-28 as the standard.
The characteristics of this assay have been reported in detail (23); the assay is sensitive to 5 pg per tube, and intra-and interassay coefficients of variation are 5% and 16%, respectively.
Measurement ofcyclic nucleotide production by isolated glomeruli and IMCD cells. Glomeruli were isolated using a modification (24) of the technique of Chaumet-Riffaud et al. (25) . Aliquots of the final centrifugation uniformly indicated a yield of material containing > 90% glomeruli with < 5% tubular contamination when examined by light microscopy. The pellet was resuspended in ice-cold 20 mM Tris (hydroxymethylaminomethane) hydrochloride buffer, pH 7.4, containing 135 mM NaCI, 10 mM KCI, 10 mM Na acetate, and 5 mM glucose (buffer A) and aliquots used for the incubations described below. IMCD cells were isolated according to the method of Zeidel et al. (26) from collagenase-digested sections of inner medulla. Samples of IMCD cells from normal and nephrotic rat kidneys were then embedded in Poly/BED 812 and examined by transmission electron microscopy using a model 100 SC microscope (JEOL USA, Peabody, MA); photographs were made at x6900. Cells from both normal and nephrotic animals exhibited the characteristic ultrastructural appearance of IMCD cells including large nuclei and pale cytoplasm with few organelles (26) ; no differences between normal and nephrotic cells were observed.
For measurement of ANP-dependent cGMP accumulation, aliquots of fresh glomeruli or IMCD cells were suspended in 350 M1 of buffer A containing 1 mM CaCl2 for glomeruli or 7.5 mM glucose but no pyruvate or acetate for IMCD cells and preincubated for 10 min at 37°C in a shaking water bath. In some preparations, isobutylmethylxanthine (IBMX) or zaprinast, each at 10-3 M, was included in the incubation medium. Incubation was started by adding synthetic rat ANP,.28 (Peninsula Laboratories, Inc., Belmont, CA) in a concentration of 10-" to 10-5 M, and terminated after 10 min by adding 750 M1 of ice cold trichloroacetic acid (TCA), final concentration 6.6%, and cooling to 4°C. The precipitated protein was sedimented by centrifugation at 4,500 rpm for 15 min at 4°C, and the pellet were dissolved in 1 N NaOH and assayed for protein content by the method ofLowry et al. (27) using bovine serum albumin as the standard. The supernatant fluid was extracted five times with four volumes of water-saturated ethyl ether to remove the TCA before being evaporated to dryness under a stream of air; it was stored at -70°until assayed for cGMP content. For the cGMP assay, samples were dissolved in 50 mM sodium acetate buffer, pH 6.2, and mixed thoroughly, and 100-MA aliquots were acetylated according to the manufacturer's instructions (New England Nuclear). Averaged results of triplicate determinations are expressed as femtomoles cGMP accumulated per 10 min-incubation per milligram protein. This same procedure was also used to determine cGMP accumulation in response to sodium nitroprusside (I0-9 to I0-, M).
We also measured the ability ofglomeruli and IMCD cells to generate cyclic AMP in response to vasopressin. Synthetic arginine vasopressin (AVP, Peninsula Laboratories, Inc.) was added to incubation medium (without IBMX) at concentrations of 10"-to I0 M; the reaction was stopped after 10 min as described above and cAMP content assayed using a commercial kit (New England Nuclear).
Measurement of binding of'25I-ANP to IMCD cells. Freshly dispersed IMCD cells were resuspended in 400 ,l of phosphate-buffered saline (PBS). Binding reactions were run in 200 jAl ofDME-H21, 0.2% bovine serum albumin, 10 mM Hepes buffer (pH 7.4), varying concentrations of 1251-ANP (5 x 10-12 to 10-9 M), phosphoramidon (8 Ag/ml) in the presence or absence of 106 M unlabeled ANP. Reactions were initiated by the addition of 10 jd of the cell suspension described above and run for 30 min at 370C. Cells were then pelleted, resuspended, washed with PBS four times at 4VC, repelleted, and lysed in 1 N NaOH (1 ml). A 900 gl aliquot was then taken for counting.
Protein determinations were made using the Coomassie Blue reagent (Pierce Biochemicals, Rockford, IL).
Data presentation and statistical analysis. Data are presented as group means± 1 standard error (SE). For the clearance experiments, urinary variables were assessed using repeated measures analysis of variance with the Bonferroni post hoc test; since values from C, never differed significantly from C2, results in these two periods were pooled to provide a single control measurement in some analyses. Comparisons among groups utilized the unpaired t test when only two groups were compared, and one way analysis of variance when three or more groups were involved. A P value < 0.05 was used to assign statistical significance.
Results
The modest volume expansion protocol used in group II experiments led to a brisk natriuresis in normal rats (group IIa) that was evident in the very first 10-min postinfusion period (E1), peaked in the second period (E2) and then declined somewhat to a level in E3 which remained above the control (Fig. 1) . In nephrotic rats (group 1Ib), an increase in UNaV in response to the administered saline was also observed, although its magnitude was markedly blunted when compared to the normal rats (Fig. 1) . More complete data from these studies as well as groups I and. III are presented in Table I, after the saline infusion, large increases occurred in both groups in E2 and then returned to baseline control values in E3. The measured increase was comparable in both groups, but was not sufficient to prevent a large increase in fractional sodium excretion (FENa) in each group, from 0.32±0.06% during control to 3.01±0.38% in E2 and 2.22±0.30% in E3 for group Iha rats (P < 0.001 for both), and from 0.24±0.07% during control to 1.49±0.23% in E2 and 1.22±0.14% in E3 for group UIb (P < 0.001 for both). However, just as with UNaV, FENa in group lIb nephrotic rats was significantly less after saline infusion than in group Ila (P = 0.007).
The volume expansion protocol was also carried out in group III rats that had undergone prior renal denervation, and these results are also shown in Table I jseq/ min 20 min after the onset ofthe infusion. In four anesthetized nephrotic rats that had undergone prior renal denervation, a blunted natriuretic response was again observed, UNaV increasing only from 0.5±0.2 to 10.8±7.0 ;eq/min, significantly less (P < 0.05) than the value in innervated normals. The adequacy of the renal denervation procedure was documented by measuring the renal content of norepinephrine in 6 innervated and 22 denervated kidneys. Renal content ofnorepinephrine was 123±25 pg/mg wet wt in innervated kidneys, and fell to 5.0±0.2 pg/mg wet wt in denervated kidneys. Thus, we were unable to demonstrate an amelioration of volume expansion natriuresis in this model of experimental nephrosis by renal denervation. Fig. 2 presents the plasma ANP concentrations obtained at the conclusion of the experiment. In the group I time control experiments plasma immunoreactive ANP was similar in normal and nephrotic rats, 103±18 and 89±26 pg/ml, respectively. 30 min after volume expansion, it was significantly elevated over control in both normals and nephrotics, the value of 201±27 pg/ml in group Ila being greater than group Ia (P < 0.05), and the value of 311±35 in group Ilb being greater than group Ib (P < 0.005). Indeed, the group Ilb value was also significantly greater than group Ha (P = 0.024), indicating that (Fig. 4) . Thus, impaired urinary excretion of cGMP by nephrotic rat kidneys in response to volume expansion in vivo was matched by blunted responsiveness of target cells to ANP in vitro, through a process specific for cGMP signaling pathway(s).
We Fig. 5 . Addition of IBMX to the incubation medium increased basal cGMP production, but again without appreciable differences between tissues from normal or nephrotic kidneys. The stimulation ofcGMP production by ANP was amplified in the presence of IBMX in both IMCD cells and glomeruli from normal and nephrotic rats at IO-' and 10-6 M. However, in both tissues, the difference between normals and nephrotics was no longer observed, as cGMP production by both glomeruli and IMCD cells from nephrotic kidneys was statistically indistinguishable from normal (Fig. 5) . These data were paralleled by the results with zaprinast. The To determine if these in vitro observations were reflective of the phenomenon of ANP resistance in vivo, we carried out the volume expansion protocol in group IV rats in which zaprinast was infused into the left renal artery at 10 $ug/min. In Fig. 6 A, data on UNaV from each kidney (infused and contralateral) of 10 normal and 14 nephrotic rats are illustrated. Intrarenal zaprinast had a small effect on basal UNaV in normal rats (ratio of infused/contralateral 1.50±0.32, P < 0.01) but increased it more strikingly in nephrotics (infused/contralateral 2.13+0.52, P < 0.01). After volume expansion, UNaV rose significantly from all kidneys, values in E2 and E3 being greater than each of the respective control periods by repeated measures ANOVA. In normal rats, zaprinast amplified volume expansion natriuresis modestly but significantly, the values of UNaV in E2 and E3 again being greater from infused than contralateral kidneys (P < 0.01). The effect of zaprinast on volume expansion natriuresis in nephrotic rats was more pronounced. Not only was UNaV much greater from the infused kidney (infused/contralateral 2.62±0.51 and 2.25±0.39 for E2 and E3, respectively, P < 0.001 for each), but the value from the infused kidneys was statistically indistinguishable from either infused or contralateral normal kidneys, and each was greater in E2 than the results from nephrotic contralateral (noninfused) kidneys (P < 0.05). Thus, intrarenal zaprinast was able to normalize volume expansion natriuresis by nephrotic kidneys. The data on UGMPV from 8 normal and 11 nephrotic group IV rats are shown in Fig. 6 B. Qualitatively similar results were observed. Intrarenal zaprinast had no appreciable effect on baseline UrGMPV, and excretion again rose after volume expansion in all groups. UCCJMPV from contralateral nephrotic kidneys in E2 was less than from contralateral normal kidneys (28. 35±3.27 vs. 48.11±10.33 pmol/min, P = 0.054), suggesting that the same defect observed in group Ilb experiments existed in these group IVb animals as well. As with UNaV, zaprinast infusion completely normalized UcMpV from nephrotic kidneys. These studies therefore indicate that zaprinast infusion in vivo is able to restore the blunted excretory response to volume expansion in nephrotic animals in a manner similar to its restoration of ANP responsiveness in vitro.
Discussion
Although some evidence suggests that sodium retention in nephrotic syndrome occurs in response to an underfilled circulation, compelling observations incriminate an abnormality intrinsic to the kidneys themselves to account for this defect. Nevertheless, the nature of this abnormality has remained obscure. The results of our experiments suggest that the defect in sodium metabolism in at least one form of experimental nephrosis, that resulting from adriamycin administration, may result from blunted cellular responsiveness to the renal actions of ANP. Other studies have documented that rats treated with adriamycin have a blunted natriuretic response to volume expansion (7) and ANP infusion (19) (20) (21) . In recent studies, renal denervation improved both the volume expansion natriuresis (7) and the natriuresis resulting from infusion of ANP IMCD cells .7
-6 tion occurred between normals and nephrotics. N~ignifi-cantly greater than value e] Nephrotic with vehicle alone, P < 0.05. (19) , suggesting that the heightened sympathetic efferent renal nerve activity observed in this model of nephrosis (7) could contribute to abnormal sodium metabolism, and perhaps the ANP resistance which characterizes this and other forms of pathological sodium retention (30) . In the present study we sought to investigate the regulation of sodium metabolism in nephrotic syndrome in the context of the resistance to ANP reported by others. (28) . We then sought to determine if enhanced degradation of the cellular cGMP produced by a normal interaction between ANP and the receptor-cyclase complex could account for the impaired cGMP levels we observed in nephrotic tissues. We used IBMX, a general inhibitor ofcyclic nucleotide PDEs, and zaprinast, an agent more specific for cGMP PDE (34) , for this purpose. IBMX increased basal, nonstimulated levels ofcGMP in both glomeruli and IMCD cells. Again, there was no difference in basal cGMP production between normals and nephrotics. As expected, cGMP levels in the presence of 1o-6 M ANP were elevated over levels from the same preparations incubated in the absence of IBMX. Zaprinast produced similar results, although levels with this compound were less elevated in glomeruli than with IBMX (P < 0.05). However, a major difference was seen in the presence vs. the absence ofthese two PDE inhibitors. After incubation with each inhibitor, the reduction in cGMP levels after exposure to ANP in cells from nephrotic tissues was virtually eliminated. Such results would therefore suggest that enhanced PDE activity contributes to the nephrotic abnormality in cGMP metabolism. This conclusion is further supported by the experiments in which cGMP production was stimulated with sodium nitroprusside, an activator of soluble guanylate cyclase. Accumulation of cGMP during incubation with this agent was also blunted in nephrotic compared to normal glomeruli, and was also totally corrected with either PDE inhibitor (Table III) . IBMX is a nonspecific inhibitor of PDEs, yet we saw no difference in nephrotics with respect to AVP-dependent cAMP stimulation. This finding suggests the possibility that differential metabolism of cyclic A c6.0 i20 nucleotides in normal vs. nephrotic cells might be confined to a specific cGMP PDE (35) , an hypothesis supported by the results with zaprinast, a compound with selectivity for this PDE isoform (34) . Direct measurement of this enzyme activity in normal and nephrotic glomeruli and IMCD cells will be an important test of this hypothesis.
To test the physiological relevance ofthese in vitro observations, we carried out the volume expansion protocol in rats receiving an intrarenal infusion of zaprinast. The volume expansion natriuresis was somewhat more robust from normal kidneys infused with zaprinast, a response also observed by Wilkins and associates (34) . However, a much more striking effect was seen in nephrotic kidneys. The contralateral, noninfused kidney exhibited blunted volume expansion natriuresis as was observed in group Ilb studies. The natriuretic response of the infused kidney, however, was much greater and, in fact, could not be distinguished from the normal response. These results were qualitatively duplicated with respect to Uc(JMPV. In aggregate, they offer strong support for the biologic importance of enhanced cGMP PDE activity as the basis for ANP resistance observed in vitro.
Our data do not allow definition of the relative contributions of the glomerular vs. IMCD cell defect in ANP-stimulated cGMP accumulation to the blunted natriuresis seen in nephrotic animals. Some data link natriuresis after ANP infusion to the increase in GFR (36, 37) , but there is strong evidence (reviewed in reference 31 ) pointing to direct inhibition of sodium transport in the IMCD. In our experiments, GFR rose after volume expansion in nephrotic animals to an extent similar to that seen in normals despite the impaired ANP-dependent cGMP accumulation that we observed in in vitro studies. Because there are multiple neural, humoral, and hemodynamic determinants of GFR that could be altered by volume expansion, the functional consequence of the in vitro defect could well be obscured, or not large enough to prevent ANPmediated hyperfiltration. However, to the extent that the changes in GFR in the two groups were comparable, our data suggest that the IMCD is the more likely ofthe two to represent the site responsible for blunted ANP-dependent natriuresis in adriamycin nephrosis. This conclusion fits with additional observations implicating a distal nephron locus for increased sodium reabsorption in nephrosis ( 1, (9) (10) (11) (12) .
In summary, we have identified an abnormality in cGMP metabolism in nephrotic rat glomeruli and IMCD cells in vitro which may account, at least in part, for the blunted volume expansion natriuresis and resistance to infused ANP found in vivo. Such an abnormality lends support to the contention that a component of nephrotic edema results from an intrarenal defect leading to salt retention. The present studies suggest the possibility that resistance to ANP may be related to enhanced activity of cGMP-PDE(s). Further study of this defect should provide new insight into the basis for pathological sodium retention in nephrotic syndrome.
